Copyright
©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Feb 7, 2011; 17(5): 545-546
Published online Feb 7, 2011. doi: 10.3748/wjg.v17.i5.545
Published online Feb 7, 2011. doi: 10.3748/wjg.v17.i5.545
What’s hot in inflammatory bowel disease in 2011?
Silvio Danese, IBD Center, Division of Gastroenterology, IRCCS Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano, Milan, Italy
Author contributions: Danese S contributed all to the paper.
Correspondence to: Dr. Silvio Danese, MD, PhD, IBD Center, Division of Gastroenterology, IRCCS Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano, Milan, Italy. sdanese@hotmail.com
Telephone: +39-2-82244771 Fax: +39-2-82244590
Received: January 4, 2011
Revised: January 18, 2011
Accepted: January 25, 2011
Published online: February 7, 2011
Revised: January 18, 2011
Accepted: January 25, 2011
Published online: February 7, 2011
Abstract
Ulcerative colitis and Crohn’s disease (CD) are the two major forms of inflammatory bowel disease (IBD). In this highlight topic series of articles, the most recent advances in the IBD field are reviewed, especially the newly described cytokines, including the therapeutic implications for their manipulation. In addition, the interplay between the intestinal microbiota and the host is reviewed, including the role of defensins and dysbiosis in CD pathogenesis. Finally, the importance of the non immune systems such as endothelial cells and the hemostatic system are highlighted as new players in IBD pathogenesis.